AMOSTOMIG
UNII 2WU34H9RT9

Substance Identification & Data

This profile provides standardized clinical and technical data for Amostomig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 2WU34H9RT9.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2889449-09-4 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

2WU34H9RT9

CAS Registry Number

2889449-09-4

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

AMOSTOMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C207407

National Cancer Institute reference terminology for clinical and research data.

INN ID

13052

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Amostomig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

AMOSTOMIG

Common Names & Synonyms

AMOSTOMIG [INN]

H-GAMMA1 HEAVY CHAIN ANTI-CD47 HUMANIZED (1-464) (VH(HOMO SAPIENS IGHV3-23*04 (83.8%) -(IGHD) -IGHJ4*01(92.3%) L123>T (129), CDR-IMGT (8.10.20) (26-33.51-60.104-123)) (1-134)-HOMO SAPIENS IGHG1*01V, G1M17,1>G1M3,1 CH1 R120, CH3 D12, L14, G1V14 CH2A1.3, A1.2, G1V74 CH3 C10, G1V32 CH3 W22 (KNOB) (CH1 R120 (231) (135-232), HINGE 1-15 (233-247), CH2 L1.3>A(251), L1.2>A (252) (248-357), CH3 D12 (373), L14 (375), S10>C (371), T22>W (383) (358-462), CHS (463-464)) (135-464)), (237-215')-DISULFIDE WITH COMMON L-LAMBDA2 LIGHT CHAIN HUMANIZED (1'-216') (V-LAMBDA (HOMO SAPIENS IGLV8-61*01 (85.6%) -IGLJ2*01 (90.9%), CDR-IMGT(9.3.10) (26'-34'.52'-54'.91'-100')) (1'-110') -HOMO SAPIENS IGLC2*01 (100%) (111'-216'))

IMMUNOGLOBULIN G1 (251-ALANINE,252-ALANINE), BISPECIFIC, ANTI-(HUMAN CD47 ANTIGEN) (HUMAN-LAMA GLAMA MONOCLONAL BCD-106 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-LAMA GLAMA MONOCLONAL BCD-106 .LAMBDA.-CHAIN (243->232'),(246->235'),(371->355')-TRIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE) ANTI-(HUMAN PROGRAMMED DEATH-LIGAND PD-L1) (HUMAN-LAMA GLAMA MONOCLONAL BCD-106 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN MONOCLONAL BCD-106 .LAMBDA.-CHAIN

IMMUNOGLOBULIN G1-LAMBDA, ANTI-(HOMO SAPIENS CD47 (CD47 MOLECULE, INTEGRIN ASSOCIATED PROTEIN, IAP, MER6, OA3)) AND ANTI-(HOMO SAPIENS CD274 (PROGRAMMED CELL DEATH 1 LIGAND 1, PDL1, PD-L1, B7 HOMOLOG 1, B7H1, B7-H1, PDCD1LG1)), HUMANIZED MONOCLONAL ANTIBODY, BISPECIFIC

External Clinical & Regulatory Resources

Previous UNII2WU1T01J5B

Next UNII2WU6VU2L3D